论文信息 - A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability - 字舞流文

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

T. Bijma | G. Fey | G. Huls | W. Helfrich | Douwe F Samplonius | M. Schwemmlein | E. Bremer | D. Samplonius | B. Cate | M. Bruyn | Michael Schwemmlein | Theo Bijma | Gerwin Huls | Georg H. Fey | Gerwin A. Huls